Accounting for 17.7 million deaths per year and 23.6 million deaths by 2030, cardiovascular disease (CVD) is the leading cause of death worldwide, surpassing cancer and other diseases. In 2020, CVD incurred a financial burden of $22.2 billion in Canada; an amount that is expected to increase alongside sociodemographic characteristics such as ageing of the population, urbanisation, and socioeconomic status, as well as environmental risk factors such as air pollution. To address this urgent global health problem, vascular grafts have proven instrumental in enhancing the quality of life in patients with CVD and are widely used to reconstruct, replace, or bypass occluded vessels. Nonetheless, adverse events such as thrombotic occlusion, calcification, and stenosis occur and often lead to device failure. Moreover, the use of synthetic graft materials in pediatric patients make future re-intervention inevitable due to their lack of growth potential. Thus, implementing strategies to improve the biocompatibility and tissue integration of vascular grafts is of great importance.